DiamiR Biosciences, which is developing blood-based tests for neurodegenerative diseases, filed on Friday with the SEC to raise up to $7 million in an initial public offering.
DiamiR Biosciences is a molecular diagnostic company focused on the development and commercialization of blood-based tests for minimally invasive risk assessment and monitoring of Mild Cognitive Impairment (MCI), Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases. The company's proprietary technology is based on quantitative analysis of circulating organ-enriched microRNAs in plasma, which tests a separate biological pathway than traditional blood protein markers interrogate. DiamiR's first test, CogniMIR, will be used by clinicians and researchers to detect and determine risk of MCI. It plans to complete a clinical validation study in 2Q25.
The Monmouth Junction, NJ-based company was founded in 2009 and booked $1 million in revenue for the 12 months ended February 29, 2024. It plans to list on the Nasdaq under the symbol DIMR. DiamiR Biosciences filed confidentially on October 13, 2023. The Benchmark Company is the sole bookrunner on the deal. No pricing terms were disclosed.
